362 related articles for article (PubMed ID: 17056271)
1. On the potential of thioredoxin reductase inhibitors for cancer therapy.
Urig S; Becker K
Semin Cancer Biol; 2006 Dec; 16(6):452-65. PubMed ID: 17056271
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302.
Li S; Zhang J; Li J; Chen D; Matteucci M; Curd J; Duan JX
Biol Trace Elem Res; 2010 Sep; 136(3):294-301. PubMed ID: 19838642
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of thioredoxin reductase by mansonone F analogues: Implications for anticancer activity.
Liu Z; Huang SL; Li MM; Huang ZS; Lee KS; Gu LQ
Chem Biol Interact; 2009 Jan; 177(1):48-57. PubMed ID: 18822278
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds.
Witte AB; Anestål K; Jerremalm E; Ehrsson H; Arnér ES
Free Radic Biol Med; 2005 Sep; 39(5):696-703. PubMed ID: 16085187
[TBL] [Abstract][Full Text] [Related]
5. Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase.
Gandin V; Fernandes AP; Rigobello MP; Dani B; Sorrentino F; Tisato F; Björnstedt M; Bindoli A; Sturaro A; Rella R; Marzano C
Biochem Pharmacol; 2010 Jan; 79(2):90-101. PubMed ID: 19665452
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
Tonissen KF; Di Trapani G
Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo.
Wang X; Zhang J; Xu T
Toxicol Appl Pharmacol; 2007 Jan; 218(1):88-95. PubMed ID: 17156807
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles.
Cassidy PB; Edes K; Nelson CC; Parsawar K; Fitzpatrick FA; Moos PJ
Carcinogenesis; 2006 Dec; 27(12):2538-49. PubMed ID: 16777982
[TBL] [Abstract][Full Text] [Related]
9. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity.
Lu J; Papp LV; Fang J; Rodriguez-Nieto S; Zhivotovsky B; Holmgren A
Cancer Res; 2006 Apr; 66(8):4410-8. PubMed ID: 16618767
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro inhibition of mice thioredoxin reductase by methylmercury.
Wagner C; Sudati JH; Nogueira CW; Rocha JB
Biometals; 2010 Dec; 23(6):1171-7. PubMed ID: 20717703
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibitors of mammalian thioredoxin reductase.
Cai W; Zhang L; Song Y; Wang B; Zhang B; Cui X; Hu G; Liu Y; Wu J; Fang J
Free Radic Biol Med; 2012 Jan; 52(2):257-65. PubMed ID: 22064364
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based inactivation of thioredoxin reductase from Plasmodium falciparum by Mannich bases. Implication for cytotoxicity.
Davioud-Charvet E; McLeish MJ; Veine DM; Giegel D; Arscott LD; Andricopulo AD; Becker K; Müller S; Schirmer RH; Williams CH; Kenyon GL
Biochemistry; 2003 Nov; 42(45):13319-30. PubMed ID: 14609342
[TBL] [Abstract][Full Text] [Related]
14. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to human thioredoxin reductase.
Söderberg A; Sahaf B; Holmgren A; Rosén A
Biochem Biophys Res Commun; 1998 Aug; 249(1):86-9. PubMed ID: 9705836
[TBL] [Abstract][Full Text] [Related]
16. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity.
Chew EH; Lu J; Bradshaw TD; Holmgren A
FASEB J; 2008 Jun; 22(6):2072-83. PubMed ID: 18180330
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of thioredoxin reductase by alantolactone prompts oxidative stress-mediated apoptosis of HeLa cells.
Zhang J; Li Y; Duan D; Yao J; Gao K; Fang J
Biochem Pharmacol; 2016 Feb; 102():34-44. PubMed ID: 26686580
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of thioredoxin reductase 1 regulates NF-kappa B activation.
Sakurai A; Yuasa K; Shoji Y; Himeno S; Tsujimoto M; Kunimoto M; Imura N; Hara S
J Cell Physiol; 2004 Jan; 198(1):22-30. PubMed ID: 14584040
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of curcumin analogues as potential thioredoxin reductase inhibitors.
Qiu X; Liu Z; Shao WY; Liu X; Jing DP; Yu YJ; An LK; Huang SL; Bu XZ; Huang ZS; Gu LQ
Bioorg Med Chem; 2008 Sep; 16(17):8035-41. PubMed ID: 18678491
[TBL] [Abstract][Full Text] [Related]
20. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
Lu J; Chew EH; Holmgren A
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12288-93. PubMed ID: 17640917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
